GlassScriptPhysician profile
Joseph C Mallette
NPI 1396298204
$8,924.98
in general payments reported to CMS, 2019-2025
25 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,816 · 2022: $2,397 · 2023: $1,640 · 2024: $1,284 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,525 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,525.30 |
| Education | $186.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,278.68 | 2021-2025 | |
| Janssen Biotech, INC. | $1,829.03 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $604.51 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $503.58 | 2021-2025 | Opzelura, Opzelura |
| Mayne Pharma Commercial LLC | $430.83 | 2021-2023 | |
| Amgen INC. | $354.90 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $347.78 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $319.18 | 2021-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $278.46 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $227.21 | 2021-2025 | Nemluvio, Epsolay, Twyneo |
| Pfizer INC. | $177.29 | 2021-2023 | |
| Genzyme Corporation | $166.79 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.08 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Leo Pharma INC. | $51.86 | 2022 | |
| Biofrontera INC. | $49.94 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $40.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $39.47 | 2024-2025 | Nuzyra |
| Kerecis Limited | $33.21 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.22 | 2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $20.00 | 2024 | Ycanth |
| Botanix Sb INC | $17.98 | 2025 | Sofdra |
| Genentech USA, INC. | $16.22 | 2023 | Erivedge |
| Journey Medical Corporation | $14.85 | 2022 | |
| Fresenius Kabi USA, LLC | $14.28 | 2023 | |
| Nabriva Therapeutics, Plc | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mallette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.